RT Journal Article
SR Electronic
T1 VIRAL LOAD SUPPRESSION AND ASSOCIATED FACTORS AMONG HIV-INFECTED PATIENTS ON SECOND-LINE ANTIRETROVIRAL THERAPY AT PUBLIC HEALTH FACILITIES OF WEST GUJI, GUJI AND BORENA ZONES, SOUTHERN ETHIOPIA: FACILITY BASED CROSS-SECTIONAL STUDY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.02.24305217
DO 10.1101/2024.04.02.24305217
A1 Hailu, Digafe
A1 Jara, Dube
A1 Edin, Alo
A1 Awol, Abdurazak
A1 Ayele, Angefa
A1 Fekadu, Yohannes
A1 Endale, Dereje
A1 Gelchu, Miesa
A1 Lemma, Kebebew
YR 2024
UL http://medrxiv.org/content/early/2024/04/03/2024.04.02.24305217.abstract
AB Background Ethiopia is one of the nation’s most severely impacted by HIV, with an estimated 700,000 people living with HIV/AIDS. Hence, many health facilities were providing second-line antiretroviral therapy, however little was known about viral load suppression among second-line users. This study aimed to assess the proportion of viral load suppression and associated factors among HIV-infected patients on second-line antiretroviral therapy at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia.Methods A facility-based cross-sectional study was conducted among 256 HIV-infected patients on second-line antiretroviral therapy from January 1, 2019, to December 30, 2022, by using census after obtaining ethical clearance from Bule Hora University ethical review committee. Data were extracted using a structured, pre-tested checklist, entered into the EPI data version 3.1.0, and exported to SPSS version 25 for analysis. The proportion of viral load suppression was determined. A binary logistic regression model was fitted to identify factors associated with viral load suppression. Statistical significance was declared at a 95% confidence interval (CI) with a P-value <0.05.Results This study revealed that the proportion of viral load suppression among HIV-infected patients on second-line antiretroviral therapy was 73.8% (95% CI, 68.0–79.1). Those who missed the second-line antiretroviral regimen [AOR = 0.315, 95% CI (0.162–0.612)], a baseline viral load count of <10,000 copies/mm3 [AOR = 2.291, 95% CI (1.216-4.316)], and a baseline body mass index of ≥18.5 kg/m2 [AOR = 2.438, 95% CI (1.098–5.414)] were significantly associated with viral load suppression.Conclusions The proportion of patients with viral load suppression fell below the WHO’s and national level. Viral load suppression was significantly influenced by missed second-line antiretroviral doses, a baseline viral load count of <10,000 copies/ml, and a baseline body mass index of ≥18.5 kg/m2. Hence interventions targeting counseling to patients that missed their antiretroviral therapy, keeping patient’s viral load to be less than 10,000 copies/ml through adequate adherence counseling among second-line antiretroviral therapy were recommended.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was secured from Bule Hora University, where I earned my MPH. Bule Hora University approved title for use and does not have any role in design of study. collection, analysis, interpretation of data, and writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:To grant access to patient records, Bule Hora University Specialized Hospital, Yabelo General Hospital, Moyale Primary Hospital, Moyale Health Center, Negele General Hospital, Adola General Hospital, Adola Health Center, and Shakiso Health Center received ethical clearance from ethical review committee of Bule Hora University, the Institute of Health with reference number of BHU/IOH/SPH/0039/2015. Data were taken from the patient's chart, laboratory request sheets, and high viral load registration logbook after obtaining consent from ART focal person of each health facility. As the data was obtained from patient records and its source was secondary data, obtaining consent from study participants were not possible. Therefore, data confidentiality was maintained throughout the study, and in accordance with the Helsinki Declaration, the data will not be utilized for any other purposes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are available from the corresponding author upon reasonable requestAIDSAcquired Immunodeficiency SyndromeARTAntiretroviral TherapyARVAntiretroviralBMIBody Mass IndexCPTCo-trimoxazole Preventive TherapyDTGDolutegravirDVSDurable Viral SuppressionFDCFixed Dose CombinationHAARTHighly Active Anti-retroviral TherapyHIVHuman Immunodeficiency VirusHTSHIV Testing ServiceILInterleukinIPTIsoniazid Preventive TherapyMDGsMillennium Development GoalsNRTINon Reverse Transcriptase InhibitorOIOpportunistic InfectionPIProtease InhibitorPLWHAPeople Living With HIV/AIDSRNARibonucleic AcidRVIRetroviral InfectionTBTuberculosistVRtransient Viral ReboundVIFVariance Inflation FactorVLSViral Load Suppression